Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

<p>Table S2</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Yun-Guang Hong (14960966) (author)
Бусад зохиолчид:	Zhigang Yang (14960969) (author), Yan Chen (14960972) (author), Tian Liu (14960975) (author), Yuyuan Zheng (14960978) (author), Chun Zhou (14960981) (author), Guo-Cai Wu (14960984) (author), Yinhui Chen (14960987) (author), Juan Xia (14960990) (author), Ruiting Wen (14960993) (author), Wenxin Liu (14960996) (author), Yi Zhao (14960999) (author), Jin Chen (14961002) (author), Xiangwei Gao (14961005) (author), Zhanghui Chen (14961008) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
-н: Amir T. Fathi (15313195)
Хэвлэсэн: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
-н: Amir T. Fathi (15313195)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
-н: Long Jiang (14956159)
Хэвлэсэн: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
-н: Long Jiang (14956159)
Хэвлэсэн: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
-н: Long Jiang (14956159)
Хэвлэсэн: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
-н: Smruthy Sivakumar (15053536)
Хэвлэсэн: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
-н: Xiangyu Zeng (17314920)
Хэвлэсэн: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
-н: Zev A. Wainberg (15047031)
Хэвлэсэн: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
-н: Jeffrey D. Mandell (14963909)
Хэвлэсэн: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
-н: Nicolas A. Giraldo (15050937)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_d719qsa7ruk53663gfd5r8qacj